CEO Executive AssistantCommercial readiness is one of the most critical organizational transitions a biotech company makes: the evolution from a development-stage company that advances science to a commercial-stage company that brings medicines to patients. For CEOs leading this transition, the organizational and leadership demands are enormous.
Clinical timelines must be managed to approval. Regulatory relationships must be maintained. Investor confidence must be sustained through the transition. And simultaneously, the commercial organization, the market access strategy, the patient support infrastructure, and the commercial launch plan must be built, often from scratch, in the 12 to 24 months before launch.
A clear delegation matrix is essential for managing this complexity. The CEO who tries to personally manage clinical advancement, commercial buildout, investor relations, and organizational development simultaneously will find it impossible. This matrix gives biotech CEOs a structured framework for distributing commercial readiness work across the appropriate leadership levels.
The Commercial Readiness Transition
Commercial readiness for a development-stage biotech involves building capabilities the organization has never needed before.
Market access infrastructure. Payer engagement, formulary strategy, health economics evidence generation, and patient assistance program design must be developed and operational before launch. Without these capabilities, even an approved drug may not reach patients.
Commercial organization buildout. Sales force hiring, training, territory design, and deployment require significant lead time. Building a commercial organization is a different kind of challenge than building a clinical team, and biotech CEOs often have limited personal experience with it.
Brand and commercial strategy. Market research, brand positioning, competitive positioning, marketing strategy, and pre-launch physician education are all commercial readiness activities that require strategic investment and specialized expertise.
Supply chain and distribution. Pharmaceutical distribution is a specialized logistics function that requires partnerships with specialty pharmacies, specialty distributors, or hospital pharmacies depending on the product’s access pathway.
Patient support programs. Reimbursement support, copay assistance, patient assistance programs, and clinical support services must be designed, approved, and operational at launch.
Medical affairs expansion. The medical affairs team must scale significantly in advance of launch, with additional MSLs hired and trained, medical information services activated, and medical education programs designed.
The Commercial Readiness Delegation Matrix
Level 1: CEO-Only (Retain)
- Commercial strategy and positioning vision
- Chief Commercial Officer and senior commercial leadership hiring and management
- Major investor communications on commercial readiness progress
- Senior payer relationship engagement at national payer level
- Board governance and commercial readiness reporting
- Major market access strategy decisions
- Partnership decisions related to commercial infrastructure
- Crisis management if commercial readiness risks emerge
Level 2: CCO and Commercial VPs (Delegate with CEO Oversight)
- Sales force design, sizing, and deployment strategy
- Marketing strategy and brand positioning development
- Market access strategy execution and payer engagement
- Medical affairs commercial readiness activities
- Commercial operations infrastructure buildout
- Patient support program design and deployment
- Digital health and technology commercial infrastructure
- Commercial forecasting and financial planning
Level 3: Directors and Managers (Delegate Fully)
- Sales representative recruitment and hiring operations
- Sales training program development and delivery
- Marketing materials development and regulatory review
- Patient support program operations
- Specialty pharmacy and distribution contracting
- Commercial analytics infrastructure buildout
- Commercial compliance training
- Field force territory alignment and routing
Level 4: Automate or Eliminate
- Approval processes below established commercial authority thresholds
- Meetings providing status without requiring decisions
- Administrative processes with available technology solutions
- Reporting generated but not used in decision-making
Hiring and Building the Commercial Leadership Team
The most critical commercial readiness delegation decision a biotech CEO makes is who leads the commercial organization. The CCO selection is a CEO-level decision with enormous implications for commercial success.
Hiring a CCO with the right therapeutic area experience, commercial launch experience, and leadership capabilities is the CEO’s responsibility. The CEO should invest significant personal attention in this hire: participating in the search, conducting thorough due diligence on candidates, and onboarding the CCO with the strategic context and organizational support needed for success.
Once the CCO is in place, the CEO should delegate commercial leadership to them with genuine authority: the CCO should have meaningful decision-making authority over commercial strategy and operations, not just an administrative reporting relationship to the CEO.
Building the rest of the commercial leadership team is the CCO’s responsibility, with the CEO engaged in final hiring decisions for direct CCO reports as appropriate.
For more detailed guidance on the pharma product launch delegation framework, see our resource on pharma product launch.
Market Access Readiness Delegation
Market access is often the most decisive determinant of launch success for specialty biotech products. Building market access readiness requires a dedicated team with specialized expertise.
A VP of market access should own market access readiness: developing the value proposition for payers, building the health economics evidence package, conducting pre-launch payer research and advisory boards, designing the market access strategy, and engaging with payers before and during launch.
The CEO engages with market access strategy at the level of major decisions: approving the pricing and access strategy, engaging with national payer leadership where CEO-level relationship investment is strategically important, and making strategic decisions when market access challenges arise.
Medical Affairs Commercial Readiness
The medical affairs team must scale significantly in advance of a commercial launch: hiring and training additional MSLs, designing the medical education program, preparing for the post-approval medical information function, and building the medical-commercial interface processes.
The CMO or head of medical affairs should own medical affairs commercial readiness: developing the medical launch plan, hiring and training the expanded MSL team, designing scientific exchange programs for target KOLs, and building the medical-commercial collaboration model.
The CEO ensures that medical affairs receives adequate resources for commercial readiness activities and that the medical-commercial interface is designed to maintain appropriate separation while enabling effective coordination.
Commercial Infrastructure and Technology
Commercial operations require technology infrastructure: CRM systems for the sales force, commercial analytics platforms, digital engagement tools for physicians, patient support technology, and commercial compliance training systems.
A commercial operations director or IT function should own commercial technology selection and implementation, working with the commercial leadership team to define requirements. The CEO makes major technology investment decisions but does not evaluate technology options operationally.
Regulatory Approval and Commercial Timing
Commercial readiness planning must be synchronized with the regulatory approval timeline. If commercial readiness is not complete at approval, the organization cannot launch effectively. If commercial readiness is complete too far ahead of approval, the organization incurs commercial infrastructure costs without generating revenue.
A commercial readiness project management function should own the timeline coordination between regulatory and commercial readiness milestones, maintaining a master commercial readiness calendar and flagging timeline risks to the CEO and leadership team.
The CEO engages when timeline risks require strategic decisions: whether to accelerate commercial investment, how to manage investor expectations if approval is delayed, and how to sequence commercial readiness investments if resources are constrained.
Patient Support Program Development
Patient support programs are essential for specialty biotech launches: reimbursement navigation, copay assistance, patient assistance programs for uninsured patients, and clinical support services are all expected by prescribers and patients in the specialty pharmaceutical market.
A patient services director or managed markets function should own patient support program development: designing program features, selecting vendors, building operational processes, training field teams, and ensuring that programs are operational at launch.
The CEO ensures that patient support programs reflect genuine organizational commitment to patient access and are adequately resourced, while delegating program design and operations to commercial and managed markets leadership.
According to McKinsey and Company, biotech companies that begin commercial readiness activities at least 24 months before anticipated approval and build dedicated commercial leadership teams achieve significantly better launch performance than those that begin commercial buildout later or that rely on the CEO to drive commercial readiness personally.
Commercial Readiness Review and CEO Oversight
As launch approaches, the CEO needs a clear and current view of commercial readiness without managing the operational details. A monthly commercial readiness review, led by the CCO and attended by the CEO, should cover the status of all major commercial readiness workstreams against the pre-launch timeline.
A commercial readiness scorecard, tracking key launch readiness criteria with red-yellow-green status indicators, gives the CEO a quick view of organizational readiness without requiring deep operational engagement.
When the scorecard reveals readiness gaps, the CEO engages with the CCO and relevant leaders to understand the issues and the resources needed to address them. This risk-based engagement keeps the CEO appropriately informed while keeping the CCO accountable for commercial readiness execution.
Board Communications on Commercial Readiness
The board of directors has fiduciary interest in commercial readiness as one of the most significant value creation events in the organization’s development. Regular board updates on commercial readiness progress are a CEO responsibility.
The CCO and commercial team should prepare commercial readiness materials for board review, with the CEO providing strategic context and presenting to the board. The CEO ensures that the board has an accurate and appropriately detailed view of commercial readiness, including realistic assessments of launch timeline risks and mitigation strategies.
The CEO’s Commercial Readiness Mindset
The biotech CEO who successfully manages the commercial transition is one who can hold two organizational identities simultaneously: the development-stage biotech culture of scientific rigor and capital efficiency, and the commercial-stage organization that must build and sustain a commercial engine.
Delegating the commercial buildout to a strong CCO and commercial leadership team while maintaining CEO-level engagement with commercial strategy, investor communication, and major market access decisions is the leadership model that makes this transition successful.
For guidance on delegating the pipeline management activities that run in parallel with commercial readiness, see our resource on pharma drug pipeline.
The patients who will benefit from your product are waiting. Build the commercial readiness organization that will reach them effectively, and delegate its operation to leaders who can deliver launch excellence.
Related Reading
For further context, explore Delegation Matrix for Arts Nonprofit CEOs and Delegation Matrix for Automotive CEO: Capital Projects.